Advertisement

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma

      Highlights

      • Dabrafenib-trametinib was efficacious in East Asians with advanced BRAF V600-mutant cutaneous melanoma.
      • Efficacy and safety of dabrafenib-trametinib in East Asians was similar to global studies.
      • No new safety findings were observed with dabrafenib-trametinib in East Asian patients.
      • Dabrafenib-trametinib could be a treatment option for East Asians with BRAF V600-mutant melanoma.

      Abstract

      Purpose

      This study (NCT02083354) assessed the efficacy and safety of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

      Method

      Overall, 77 patients of East Asian origin (including 61 from Mainland China) with unresectable or metastatic BRAF V600-mutant cutaneous melanoma were enrolled. Prior treatment was allowed except with BRAF/MEK inhibitors. Patients received dabrafenib 150 mg twice daily and trametinib 2 mg once daily. The primary end-point was objective response rate (ORR) using Response Evaluation Criteria in Solid Tumours 1.1. Secondary end-points were duration of response (DOR), progression-free survival (PFS), overall survival (OS), pharmacokinetics and safety.

      Results

      At data cutoff (February 23, 2018; median follow-up, 8.3 months), treatment was ongoing in 36 patients (47%). The median age was 52 years; 32% of patients had elevated lactate dehydrogenase, and 84% had received prior systemic therapy. ORR was 61% (95% confidence interval: 49.2–72.0), with four patients (5%) achieving complete response. Median DOR and PFS were 11.3 and 7.9 months, respectively. Median OS was not reached. The most common adverse event (AE) of any grade was pyrexia (56%). Grade ≥III AEs occurred in 29 patients (38%). The most common grade ≥III AEs were pyrexia (8%) and anaemia (6%). AEs led to permanent discontinuation in five patients (6.5%). Mean Cmax for dabrafenib and trametinib was 3560 and 11.5 ng/mL (day 1) and 2680 and 27.1 ng/mL (day 15), respectively.

      Conclusion

      These results support the efficacy and tolerability of dabrafenib in combination with trametinib in East Asian patients with unresectable or metastatic BRAF V600-mutant cutaneous melanoma.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • Siegel R.L.
        • Torre L.A.
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Chang J.W.
        • Yeh K.Y.
        • Wang C.H.
        • Yang T.S.
        • Chiang H.F.
        • Wei F.C.
        • et al.
        Malignant melanoma in Taiwan: a prognostic study of 181 cases.
        Melanoma Res. 2004; 14: 537-541
        • Bellew S.
        • Del Rosso J.Q.
        • Kim G.K.
        Skin cancer in Asians: part 2: melanoma.
        J Clin Aesthet Dermatol. 2009; 2: 34-36
        • Jakob J.A.
        • Bassett Jr., R.L.
        • Ng C.S.
        • Curry J.L.
        • Joseph R.W.
        • Alvarado G.C.
        • et al.
        NRAS mutation status is an independent prognostic factor in metastatic melanoma.
        Cancer. 2012; 118: 4014-4023
        • Long G.V.
        • Menzies A.M.
        • Nagrial A.M.
        • Haydu L.E.
        • Hamilton A.L.
        • Mann G.J.
        • et al.
        Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
        J Clin Oncol. 2011; 29: 1239-1246
        • Ihle M.A.
        • Fassunke J.
        • Konig K.
        • Grunewald I.
        • Schlaak M.
        • Kreuzberg N.
        • et al.
        Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
        BMC Canc. 2014; 14: 13
        • Maldonado J.L.
        • Fridlyand J.
        • Patel H.
        • Jain A.N.
        • Busam K.
        • Kageshita T.
        • et al.
        Determinants of BRAF mutations in primary melanomas.
        J Natl Cancer Inst. 2003; 95: 1878-1890
        • Viros A.
        • Fridlyand J.
        • Bauer J.
        • Lasithiotakis K.
        • Garbe C.
        • Pinkel D.
        • et al.
        Improving melanoma classification by integrating genetic and morphologic features.
        PLoS Med. 2008; 5 (e120)
        • Si L.
        • Kong Y.
        • Xu X.
        • Flaherty K.T.
        • Sheng X.
        • Cui C.
        • et al.
        Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.
        Eur J Canc. 2012; 48: 94-100
        • Long G.V.
        • Stroyakovskiy D.
        • Gogas H.
        • Levchenko E.
        • de Braud F.
        • Larkin J.
        • et al.
        Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
        Lancet. 2015; 386: 444-451
        • Long G.V.
        • Hauschild A.
        • Santinami M.
        • Atkinson V.
        • Mandala M.
        • Chiarion-Sileni V.
        • et al.
        Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.
        N Engl J Med. 2017; 377: 1813-1823
        • Planchard D.
        • Besse B.
        • Groen H.J.M.
        • Souquet P.J.
        • Quoix E.
        • Baik C.S.
        • et al.
        Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
        Lancet Oncol. 2016; 17: 984-993
        • Subbiah V.
        • Kreitman R.J.
        • Wainberg Z.A.
        • Cho J.Y.
        • Schellens J.H.M.
        • Soria J.C.
        • et al.
        Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer.
        J Clin Oncol. 2018; 36: 7-13
        • Robert C.
        • Karaszewska B.
        • Schachter J.
        • Rutkowski P.
        • Mackiewicz A.
        • Stroiakovski D.
        • et al.
        Improved overall survival in melanoma with combined dabrafenib and trametinib.
        N Engl J Med. 2015; 372: 30-39
        • Robert C.
        • Grob J.J.
        • Stroyakovskiy D.
        • Karaszewska B.
        • Hauschild A.
        • Levchenko E.
        • et al.
        Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma.
        N Engl J Med. 2019; 381: 626-636
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Canc. 2009; 45: 228-247
        • Oken M.M.
        • Creech R.H.
        • Tormey D.C.
        • Horton J.
        • Davis T.E.
        • McFadden E.T.
        • et al.
        Toxicity and response criteria of the eastern cooperative Oncology group.
        Am J Clin Oncol. 1982; 5: 649-655
        • Davies M.A.
        • Saiag P.
        • Robert C.
        • Grob J.J.
        • Flaherty K.T.
        • Arance A.
        • et al.
        Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 863-873
        • Lee H.Y.
        • Chay W.Y.
        • Tang M.B.
        • Chio M.T.
        • Tan S.H.
        Melanoma: differences between asian and caucasian patients.
        Ann Acad Med Singapore. 2012; 41: 17-20
        • Wang Y.
        • Zhao Y.
        • Ma S.
        Racial differences in six major subtypes of melanoma: descriptive epidemiology.
        BMC Canc. 2016; 16: 691
        • Chan J.C.
        • Malik V.
        • Jia W.
        • Kadowaki T.
        • Yajnik C.S.
        • Yoon K.H.
        • et al.
        Diabetes in Asia: epidemiology, risk factors, and pathophysiology.
        J Am Med Assoc. 2009; 301: 2129-2140